To investigate the correlation between the GDPD5 expression in esophageal carcinoma and multiple metabolic parameters of 18F-FDG PET/CT.MethodsWe retrospectively analyzed preoperative 18F-FDG PET/CT data of 53 ESCA patients and calculated their metabolic parameters value: SUVmax,SUVmean,MTV and TLG.Immunohistochemical(IHC)analysis was performed to detect levels of GDPD5,Ki67,CD31 and GLUT1 expression in ESCA.Next,we silenced GDPD5 expression using two types of small interfering RNAs(si RNAs),then applied Western blot,quantitative real-time polymerase chain reaction(q RT-PCR),MTS,Wound scratch,and colony formation assasys as well as flow cytometry to determine the effect of GDPD5 knockdown on two types of esophageal carcinoma cells.ResultsImmunohistochemical results showed that GDPD5,Ki67,CD31 and GLUT1 were significantly up-regulated in esophageal carcinoma tissues compared with normal esophageal tissues(P < 0.001).High expression of GDPD5 was significantly associated with prognosis of esophageal carcinoma patients(P =0.041).In addition,GDPD5 and GLUT1 expression were significantly correlated with tumor size(P = 0.016;P = 0.037),expression of GDPD5 was positively correlated with SUVmax,Suvmean and TLG(P = 0.002,R = 0.415;P =0.001,R = 0.442;P = 0.047,R = 0.274),but not with MTV.Moreover,GLUT1 upregulation was positively correlated with SUVmax(P = 0.002,R =0.487),SUVmean(P = 0.01,R = 0.414),TLG(P = 0.007,R = 0.429),and MTV(P = 0.009,R = 0.417).Furthermore,silencing of GDPD5 not only inhibited proliferation,migration and colony formation ability,but also promoted apoptosis,of both KYSE150 and ECA109 cells.Western blots and q RT-PCR results showed that GDPD5 was significantly correlated with GLUT1 and GLUT2(P < 0.05).SUVmax was the primary predictor of GDPD5 expression by ESCA(P = 0.009).ConclusionsCollectively,these results indicate that GDPD5 plays an important role in progression of esophageal carcinoma,with its overexpression correlated to18F-FDG PET/CT metabolic parameters.This has significant implications in diagnosis of esophageal carcinoma. |